2022 Fiscal Year Final Research Report
Validation of cytotoxic T cell activity when immune checkpoint inhibitors are combined with other cancer treatments
| Project/Area Number |
19K16866
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | immunotherapy / Cytotoxic T lymphocyte / anti-PD-1 antibody / anti-CTLA-4 antibody / cancer peptide vaccine |
|---|
| Outline of Final Research Achievements |
Sufficient results could not be obtained regarding the verification of useful combination therapy such as combined immunotherapy in cancer treatment.
Lymphocytes stimulated with anti-PD-1 antibody, anti-CTLA-4 antibody, and cancer peptide were co-cultured with tumor cells and evaluated for cytotoxic activity. However, in the verification under combined use, the reaction with cancer peptide was very weak and difficult to evaluate. Moreover, there was no difference in cell surface markers and cytokines related to immune reaction. Stimulation of only lymphocytes, which is different from biological reactions, is thought to be due to weak relationships between immune cells. We also tried co-culturing and stimulating lymphocytes and monocytes, but we were not able to obtain sufficient results.
|
| Free Research Field |
がん免疫
|
| Academic Significance and Societal Importance of the Research Achievements |
がんに対する免疫療法は長期の治療効果が得られる可能性があるが、免疫複合療法での免疫関連有害事象のような副作用問題や治療効果の予測因子が十分解明されていないことが現状の課題である。これらを解明するために、in vivoで多くの有用な報告がされているが、人への適応となると十分な効果が得られない。そのため人の細胞を使用し、in vitroで検証が可能となれば早期にこれらの課題が解明される可能性がある。本研究課題において十分な成果は得られなかったが、本検証内容をさらに発展させることで、生体内に近い反応をin vitroで検証できるようになる可能性があると考える
|
